Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.
about
Hepatitis C and HIV co-infection: new drugs in practice and in the pipelineHuman immunodeficiency virus and liver disease forum 2010: conference proceedingsPharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsLack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load.Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variantsThe cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virusLiver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patientsPredicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapyDeciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patientsTest of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.Clinical utility of pharmacogenomics in the management of hepatitis C.Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C.Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection.Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patientsHCV and HIV co-infection: mechanisms and management.IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients.IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in CaucasiansInterferon lambdas: the next cytokine stormIL28B genotype does not correlate with HIV control in African Americans.Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort.Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypesProgression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rs12979860 polymorphism of the IL28B gene.Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.Prevention of hepatitis C recurrence after liver transplantation: An update.IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patientsPharmGKB summary: peginterferon-α pathway.Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection.IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based testIL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance predictionIL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.Management of hepatitis C virus infection: the basicsImpact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIVIL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirinPrevalence of interleukin-28B single nucleotide polymorphism genotypes in patients with hepatitis C infection in Isfahan, IranIn HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use.Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision Making
P2860
Q27022596-7ECAC6A7-6C9A-44E9-B620-26A07AFC6960Q28674930-E35C07B8-9D78-4FB9-BC50-9DF35719733EQ30365599-2818BFBA-6008-4716-A51F-D6FCDF957A35Q31109635-D7071EC3-91B6-4388-811C-139AFB93EC52Q33404251-79A21DBA-7392-4DAF-9A1E-2A0C0CC0D7BEQ33710740-40BB0EAB-175A-4605-A0C7-1A2D659ABFEDQ33737419-953BE8B9-6CDE-4F3C-BA8B-F5E5EE48DE19Q33807010-1C455DB5-B615-4DD5-9072-33BA1054DAE8Q33889885-64F57B35-9621-4FE9-849F-1A8F6A5A9917Q33948641-BD9BE206-765D-4D48-82C3-6F51CF873948Q34049322-01182F19-64A2-47B9-AFAF-C13394233235Q34157284-7848F51A-7AB6-46B4-974B-80D2041EF3C5Q34429833-1437AA50-F513-4243-8512-0A5E72A87C46Q34464613-30D75731-0608-4181-AC53-10C792C9E87CQ34772812-5A393C57-3D6D-4B27-85CB-606CDF83AE95Q34796111-2FE64285-A198-4369-835C-E7DC77F067D1Q35077010-B3041FB3-5B3C-458F-AD98-29A11D3B5BB1Q35090634-0BDB3385-D0B9-4A69-8D39-7A12A5DFA06EQ35146008-55084E06-3F63-43A3-952E-2D991CA770E1Q35153222-8A059D12-0FF1-4FB3-85CD-CBDD998E0C70Q35154826-5FDA3394-E28D-4758-B8B2-C027080F8008Q35205904-D37597C1-4619-4713-841D-D74D942EBDFCQ35238151-02986011-6E07-493F-981B-6C88787E4EF8Q35610571-F50E1B99-8DBE-4593-9399-4EDDA348DF3FQ35768047-BD1B71FD-A71D-4A87-B8F2-E2F527D744CBQ35959126-788F66D4-7E0D-4E78-95BC-1161E76B0BBCQ35992420-E63F9749-0B5D-4AD0-BFD8-40FDA738603AQ36220172-73F4A223-B825-44BA-A07B-215EDB9DD409Q36541206-8DDAEDC6-48D5-4164-A674-5F0F4DFB9952Q36590755-484A901A-2B8D-47F1-80BB-4220EF25535CQ36698602-3DCBAA2E-F998-461B-8C3D-DED9286C7E5AQ36836988-563EAA2E-E07A-42F1-9879-EAC6BCF6B44FQ36907926-990D5786-C7C6-4F60-8097-9862D917BEAEQ36949481-4103DD31-C44B-4B42-87B3-068AB464C9CEQ36949500-24D8A652-75D5-4EDE-A514-1CF5BE6BE704Q36963652-53BE89A0-08A6-44A1-9EFA-D27FCBC4C14FQ36967094-20DF15EA-441B-40AF-8514-8780850A6675Q37006729-6F408A32-C021-4A77-9A68-4A687BAF67ABQ37016495-419D2B7F-95C8-454F-B260-26286CDE5EE6Q37613481-A13E2215-B86F-4B3F-B22C-BA61E8C0DB5B
P2860
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Association of a single nucleo ...... s C virus-coinfected patients.
@en
type
label
Association of a single nucleo ...... s C virus-coinfected patients.
@en
prefLabel
Association of a single nucleo ...... s C virus-coinfected patients.
@en
P2093
P2860
P1433
P1476
Association of a single nucleo ...... is C virus-coinfected patients
@en
P2093
Alex Thompson
Clara Restrepo
David Goldstein
Eugenia Vispo
John McHutchison
José M Benito
José Medrano
Kevin V Shianna
Susanna Naggie
P2860
P356
10.1097/QAD.0B013E3283391D6D
P407
P577
2010-05-01T00:00:00Z